PURPOSE: Androgen deprivation therapy (ADT) may promote the development of MetS in prostate cancer (PCa) patients.
We assessed the prevalence of full MetS and its components during the first year of ADT.
MATERIALS AND METHODS: This observational, multicentre, prospective study included 539 PCa patients scheduled to receive 3-monthly depot LH-releasing hormone analogs for > 12 months. Waist circumference, body mass index (BMI), lipid profile, blood pressure (BP), and fasting glucose were evaluated at baseline and after 6 and 12 months. MetS was assessed according to NCEP ATP III criteria (2001) and four other definitions (WHO 1998, AACE 2003, AHA/NHLBI 2005, and IDF 2005).
RESULTS: At 6 and 12 months after initiation of ADT, significant increases were observed in waist circumference, BMI, fasting glucose, triglycerides, total cholesterol, HDL cholesterol, and LDL cholesterol. No significant changes in BP >130/85 were detected. A non-significant increase of 3.9% in full MetS prevalence (ATP III) was observed (22.9% at baseline vs. 25.5% and 26.8% at 6 and 12 months, respectively). MetS prevalence at baseline varied according to the definition used , ranging from 9.4% (WHO) to 50% (IDF). At 12 months, significant increases in prevalence were observed under the WHO (4.1%) and AHA/NHLBI (8.1%) definitions.
CONCLUSIONS: ADT produces significant early effects on waist circumference, BMI, fasting glucose, triglycerides, and cholesterol. The prevalence of and increase in MetS is dependent on the defining criteria. Counselling patients on prevention, early detection, and treatment of specific metabolic alterations is recommended.
Morote J, Gómez-Caamaño A, Alvarez-Ossorio JL, Pesqueira D, Tabernero A, Gómez Veiga F, Lorente JA, Porras M, Lobato JJ, Ribal MJ, Planas J. Are you the author?
Department of Urology, Hospital Vall d'Hebron and Universitat Autónoma de Barcelona, Barcelona, Spain; Department of Radiation Oncology, Hospital Clínico Universitario Santiago de Compostela; Department of Urology, Hospital Universitario Puerta del Mar; Department of Urology, Hospital Universitario Povisa; Department of Urology, Hospital Universitario La Paz; Department of Urology, Hospital A Coruña; Department of Urology, Hospital del Mar; Department of Radiation Oncology, Hospital Universitario Virgen de la Arrixaca; Department of Urology, Hospital General Universitario d´Alacant; Department of Urology, Hospital Clínic i Provincial de Barcelona; Department of Urology, Hospital Vall d'Hebron and Universitat Autónoma de Barcelona, Barcelona, Spain.
Reference: J Urol. 2014 Dec 22. pii: S0022-5347(14)05140-4.